Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy
NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...
Hainan Province Unveils Measures to Support Innovative Drugs and Medical Devices Development
Hainan provincial bureaus, including the Healthcare Security Administration (HSA), Healthcare Commission, and Medical Products Administration,...
Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel
The Shanghai medical products administration has released the “Measures for the Management of Key Quality...
USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo
In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...
Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges
Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model...
Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results
Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...
Shanghai Enhances Biomedicine IP Protection with New Procurement-Linked Measures
The Shanghai Intellectual Property Administration (SIPA) has issued a notification highlighting the city’s intensified efforts...
Hansoh Pharmaceutical Advances Schizophrenia Treatment with HS-10509 Clinical Trial Approval
Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials...
Sino Biopharmaceutical Receives NMPA Approval for Generic Revolade Equivalent
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in the Chinese pharmaceutical industry, announced that...
Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Regenxbio’s One-Time Gene Therapy for Wet AMD Shows Promise in Phase II Study
Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study...
Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US...
China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes
The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have...
Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC
The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...
Changchun High & New Technology Industries to Launch GenSci125 Phase I Trial in US
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading Chinese pharmaceutical company,...
Hengrui Pharmaceuticals Receives NMPA Approval for Phase II Cervical Cancer Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Roche’s Tecentriq SC Receives European Nod as First Subcutaneous PD-(L)1 Therapy
Halozyme Therapeutics (NASDAQ: HALO) has announced that the European Commission (EC) has granted marketing authorization...
Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China
Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of...
Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals
Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans...
Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has...